Brenus Pharma raises €11 million Series A extension to advance immunotherapy for hard-to-treat solid tumors

Lyon-based clinical-stage biotech startup Brenus Pharma, which aims to prevent cancer recurrence, has announced an €11 million ($12.6 million) extension to its Series A round. The company's total capital raised since inception now stands at €38 million.

The round saw strong follow-on participation from existing investors, including Angelor, UI Investissement (managing FRAI), Crédit Agricole (CACE Création, CACF Capital Innovation), Noshaq, Orsa (formerly Investsud), BIO JAG, and Bpifrance (through non-dilutive funding). Two new international investors, Sambrinvest and Korea Omega Investment Corp, also joined.

Founded in 2019, Brenus Pharma develops an off-the-shelf platform for novel immuno-oncology modalities. Its precision technology mimics tumor protein expression, making it visible to the immune system and enabling a multi-specific in vivo immune response that adapts to tumor evolution. The platform targets the estimated 85% of solid tumors that are immunologically "cold" and largely unresponsive to current immunotherapies.

The company's lead candidate is STC-1010, a next-generation in vivo allogeneic immunotherapy built on Stimulated Ghost Cells (SGC) technology, targeting metastatic colorectal cancer (mCRC). The U.S. Food and Drug Administration (FDA) recently accepted the company's Investigational New Drug (IND) application for STC-1010 in microsatellite stable (MSS) metastatic colorectal cancer.

Brenus Pharma plans to use the capital to advance STC-1010 (NCT06934538) through its Phase I program and unlock the broader potential of its platform across hard-to-treat solid tumors. This financing also strengthens the company's international momentum and provides resources to reach its next clinical and strategic milestones.